Page 2 - Exsight Ventures News Today

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Disease (Dry Eye, Glaucoma), By Dosage Form, By Route of Administration, By...

Valitor Announces the Closing of its Series B Financing and Names Steven Lo as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today announced that it has closed a Series B financing and named

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Micro funds are becoming louder and more specialized as they compete to show the value they can add to early-stage companies.

ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on $46.9m in a Series B financing round. The round included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round include ONL Therapeutics management, InFocus Ca...

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months December 22, 2020 07:00 ET | Source: ONL Therapeutics ONL Therapeutics Ann Arbor, Michigan, UNITED STATES ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSW...